Table 3.

Model to Assess Determinants of Markers of Arterial Injury and Inflammation among HIV-infected Individuals

	LpPLA2 Activity (nmol/min/mL)		Oxidized LDL (U/L)		Hs-cTnT (ng/L)		hsCRP (mg/L)
	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value	β Estimate	P Value
	(R²=0.20; P=0.02)		(R²=0.20; P=0.02)		(R²=0.20; P=0.02)		(R²=0.20; P=0.02)
SAT (cm²)	−0.0896	0.04	0.0192	0.13	−0.0195	0.005	0.0041	0.20
VAT (cm²)	0.2194	0.001	0.0478	0.02	0.0212	0.04	0.0103	0.04
Duration of HIV (years)	−0.0842	0.94	0.0905	0.78	0.3214	0.07	−0.2068	0.01
Duration of ART use (years)	1.8323	0.18	0.5445	0.17	−0.1945	0.36	0.1373	0.17
CD4+ nadir count (cells/μL)	−0.0168	0.62	−0.0023	0.82	−0.0060	0.27	−0.0027	0.29
Log₁₀ HIV viral load (copies/mL)	−13.8512	0.41	−3.5921	0.46	4.9540	0.06	2.0334	0.10
Age (years)	−0.5370	0.55	−0.0267	0.92	−0.0488	0.73	0.0958	0.15

R² represents the coefficient of determination and the proportion of variance explained by the model. P value represents significance by the whole model ANOVA test.

Abbreviations: LpPLA2, lipoprotein-associated phospholipase A2; LDL, low density lipoprotein; hs-cTnT, high sensitivity cardiac troponin T; hsCRP, high-sensitivity C-reactive protein; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue